Novo Nordisk's Buyback Machine Grinds On as Investors Wait for the Pipeline to Answer Back
Published on 09/09/2026 at 15:03 | Editorial boerse-global.de
There is a quiet arithmetic at the heart of Novo Nordisk's current market narrative. Since early February, the Danish drugmaker has been steadily repurchasing its own B-shares, and the tally through September 4 stands at 32,034,179 shares bought back at an average price of 281.63 Danish kroner apiece. That works out to roughly 9.02 billion kroner deployed into the buyback, leaving the company holding 46,074,876 treasury B-shares — equivalent to 1.0 percent of its share capital. The program, which runs until February 3, 2027, is built around a 12-month plan worth up to 15 billion kroner in total.
The persistence of that buyback is itself a message. Management is effectively saying it believes the stock is cheap even as the shares drift lower — the equity changed hands at around 38.60 euros in recent trading, down 1.0 percent on the day and off 6.3 percent over the past month. The 50-day moving average sits at 41.45 euros, which means the current price is roughly 6.2 percent below that benchmark. Technical indicators do little to brighten the picture: the relative strength index reads 42.5, and annualized volatility of 40 percent points to a market that remains skittish about the company's trajectory.
A Pipeline That Keeps Losing Limbs
The bearish undertow is not hard to trace. Novo Nordisk has now pulled the plug on two more Phase 3 trials of Ziltivekimab in heart failure, following an independent data monitoring committee's assessment that there was a "low probability" the results would diverge meaningfully from the earlier failed study. Only one study remains — in post-heart-attack patients — with readouts not expected until the first half of 2027. The cardiology retreat narrows the company's footprint beyond its diabetes and obesity stronghold, deepening its reliance on the semaglutide franchise.
There was also the second-quarter writedown on Monlunabant, another pipeline asset that failed to live up to expectations. Taken together, the setbacks have fed a narrative of a pipeline in need of reinvention — and that is precisely what investors hope to hear more about on September 21, when Novo Nordisk hosts its capital markets day in London. The executive management team is expected to lay out strategy, pipeline priorities, and the operational outlook in detail, and the stakes are elevated given how much of the growth story now hinges on what comes after the established injectable GLP-1 products.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The Counterweights: Paediatric Data and an Oral Pivot
Yet the pipeline news is not uniformly grim. Semaglutid delivered a win in the STEP-Young study, hitting its primary endpoint: among children aged 6 to under 12 with full treatment adherence, 40.4 percent were no longer classified as obese after 68 weeks. That opens a commercially untapped segment in paediatric obesity, and the market has yet to price in its potential.
Meanwhile, the oral version of Wegovy is beginning its commercial life. The tablet launched in Germany roughly a week ago, and China has initiated its regulatory review of the oral formulation. These are early but meaningful steps in a broader effort to defend market share against Eli Lilly, whose Mounjaro has just received FDA approval for reducing cardiovascular risk in high-risk Type 2 diabetes patients — a move that Reuters notes intensifies competitive pressure on Novo Nordisk's wider GLP-1 ambitions.
The US pricing picture adds another layer of complexity. Under the so-called TrumpRx channel, Ozempic and Wegovy are slated to cost 350 dollars per month going forward. That concession could, in theory, drive enough volume growth to offset thinner margins — but it cuts both ways if the hoped-for uptake fails to materialize.
Fundamentals Versus Sentiment
Beneath the share-price noise, the operating story has actually improved. Second-quarter adjusted revenues rose 7 percent on a currency-adjusted basis to 78.488 billion kroner, while adjusted operating profit climbed 11 percent to 33.389 billion kroner. That prompted management to lift its full-year guidance: instead of a possible 5 to 13 percent decline in adjusted sales and profit growth, the company now guides for a range of 0 to minus 6 percent on a currency-adjusted basis.
That upgrade is part of the backdrop against which the buyback should be judged. With the stock trading visibly below its recent average, the case for continued repurchases at current levels is reasonably straightforward — at least from the boardroom's perspective. Whether shareholders agree may become clearer after the London capital markets day, where the strategic contours of the pipeline are expected to sharpen.
The next scheduled catalyst after that is the third-quarter results on November 4. Until then, the buyback remains a steady drumbeat of confidence, even as the share price continues to reflect a market weighing a paediatric milestone against a cardiology wound, an oral launch against a formidable competitor, and a raised guidance against a pipeline that has lost some of its former breadth. The stock, notably, sits roughly 29 percent below its 52-week high of 54.86 euros, with the 52-week low at 30.25 euros — a wide band that captures just how much uncertainty is currently priced into the equity.
Ad
Novo Nordisk Stock: New Analysis - 9 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
